Disney Plans to Cut 1,000 Jobs Amid Ongoing Restructuring Efforts 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Volkswagen Q1 2026 Sales Decline Amid China and U.S. Market Pressures 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
AI Deradicalization Tools: How Chatbots Could Help Combat Violent Extremism Online 
United Airlines Eyes Merger with American Airlines in Potential Industry-Shaping Deal 
SEATTLE, Feb. 14, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of universal donor cellular therapies for the treatment of patients with blood cancers, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Dr. Colleen Delaney, Nohla’s Scientific Founder and Chief Medical Officer, is scheduled to present on Tuesday, March 7th at 2:00pm ET.
Dr. Delaney’s presentation will provide an overview of the Company’s ex vivo expansion platform, which enables expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). In addition, Dr. Delaney will profile Nohla’s two lead programs evaluating the ability of these products to reduce infection and other complications of neutropenia in multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
About Nohla Therapeutics
Nohla Therapeutics Inc. (Nohla) is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with life threatening blood cancers. The Company is leveraging a platform developed over the past two decades at Fred Hutchinson Cancer Research Center which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). Nohla is evaluating the ability of these “off-the-shelf” cryopreserved expanded cell products to reduce infection and other complications of neutropenia in several clinical settings including two lead programs involving multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). Nohla is supported by top-tier healthcare dedicated institutional investors including ARCH Venture Partners, 5AM Ventures, and Jagen Group.
For more information, please contact: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Esther Cuno Director, Corporate Communications +1 206 519 5313 [email protected]
